As advised via PHARMAC tender of 29 June 2018 and our Early Notification dated 26 November 2018 there is to be a change in the listing and future sole supply.

New listing from 1 January 2019

Varenicline Pfizer Tab 0.5 mg x 11 & 1 mg x 42, 53 tablet blister pack. Pharmacode 2553155                                                     Schedule price $25.64

Varenicline Tab 1 mg 56  tablet blister pack.                                           Pharmacode 2553163                                                           Schedule price $27.10

Incumbent brand

Champix Tab 0.5 mg x 11 & 1 mg x 14, 25 tablet blister pack              Pharmacode 2380455                                  Schedule price $60.48                     Subsidy reduced to $12.09 from 1 March 2019 and delisted 1 June 2019.

Champix Tab 1 mg 56 tablet blister pack                                                  Pharmacode 2251604                                               Schedule price $135.48             Reference pricing to apply from 1 March 2019 and delisted 1 June 2019.

Champix Tab 1 mg 28 tablet blister pack (SOLD OUT)                                                  Pharmacode 2251612                                           Schedule price $67.74            Subsidy reduced to $13.55  from 1 March 2019 and delisted 1 June 2019.

Reference pricing will apply as above from 1 March 2019.

HSS (Hospital Supply Status) commences 1 March 2019  and CSS (Community Supply Status) commences 1 June 2019.

As of the date of this notification ProPharma / PWR cannot accept Champix (any) for credit under any circumstances.

Pfizer will not be supplying Champix brand into the market effective from 12 December 2018, which should give ample time for the supply chain to sell through well before reference pricing is applied 1 March 2019.

We strongly would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Yes there are logical benefits in staying with the incumbent for as long as practical and in particular you profitability.

Based on the information above you should not get caught with stock.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author